Muthiah Vaduganathan, MD: Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1 RAs

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this episode of the Endocrine Outlook, listeners will hear a conversation with Muthiah Vaduganathan, MD, MPH, a cardiologist at Brigham and Women’s hospital. Vaduganathan was also the member of the writing committee for a recent AHA scientific statement regarding the cardionrenal protective benefits of SGLT2 inhibitors and GLP-1 receptor agonists.

Episode metadata supplied by the publisher feed · Published Oct 8, 2020

Embed this episode

Attribution link and audio player

NOW PLAYING

Muthiah Vaduganathan, MD: Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1 RAs

0:00 25:47

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 25 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on October 8, 2020.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!